In the initial study of semaglutide, in the second year patients lost on average an extra 8% of their body weight
When one pathway is targeted in isolation, the body often compensates through alternative metabolic routes (e.g., increased hunger signals when fat oxidation increases)
[1] [2] GLP-1 medications work through several complementary mechanisms: Enhancing insulin secretion : They stimulate the pancreas to release insulin when blood glucose levels are elevated, helping to lower blood sugar in a glucose-dependent manner Suppressing glucagon release : They reduce the secretion of glucagon, a hormone that raises blood glucose, thereby preventing excessive glucose production by the liver Slowing gastric emptying : They delay the rate at which food leaves the stomach, leading to more gradual glucose absorption and increased feelings of fullness Reducing appetite : They act on areas of the brain involved in appetite regulation, helping to decrease food intake [2] [22] Commonly prescribed GLP-1 receptor agonists in the UK include semaglutide (Ozempic for diabetes, Wegovy for weight management, Rybelsus as an oral formulation), dulaglutide (Trulicity), liraglutide (Victoza for diabetes, Saxenda for weight management), and exenatide (Byetta, Bydureon)
As with any new medication, I suggest you have a discussion with your AME prior to starting the medication
Addressing the complexity of interference The ideal assay is specific and free from interference, but biological matrices are complex
